Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.
about
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Mutational status of TP53 defi ...... nt non-small cell lung cancer.
@en
Mutational status of TP53 defi ...... nt non-small cell lung cancer.
@nl
type
label
Mutational status of TP53 defi ...... nt non-small cell lung cancer.
@en
Mutational status of TP53 defi ...... nt non-small cell lung cancer.
@nl
prefLabel
Mutational status of TP53 defi ...... nt non-small cell lung cancer.
@en
Mutational status of TP53 defi ...... nt non-small cell lung cancer.
@nl
P2093
P2860
P356
P1433
P1476
Mutational status of TP53 defi ...... nt non-small cell lung cancer.
@en
P2093
Jin Seok Ahn
Jong-Mu Sun
Keunchil Park
Myung-Ju Ahn
Se-Hoon Lee
Yeon-Hee Bae
P2860
P304
67526-67537
P356
10.18632/ONCOTARGET.18728
P407
P577
2017-06-28T00:00:00Z